Safety of Tinidazole and Metronidazole in Pediatric Patients with G6PD Deficiency

Evidence-Based Medication Safety in G6PD Deficiency

• According to comprehensive medication safety reviews, only seven medications are definitively contraindicated in G6PD deficiency: dapsone, methylthioninium chloride (methylene blue), nitrofurantoin, phenazopyridine, primaquine, rasburicase, and tolonium chloride (toluidine blue) 1

Clinical Considerations for G6PD-Deficient Pediatric Patients

• The severity of G6PD deficiency varies based on genetic variant, with Mediterranean variants (Gdmed) typically causing more severe reactions than African variants (GdA-) 1, 2
• When treating G6PD-deficient pediatric patients with any medication, monitoring for signs of hemolysis is recommended, including jaundice, dark urine, fatigue, and pallor 3, 2

Practical Recommendations for Using Nitroimidazoles in G6PD-Deficient Children

• Ensure proper dosing based on weight and indication 4
• Monitor for any signs of hemolysis, particularly in children with more severe G6PD deficiency variants 3, 2
• Consider baseline hemoglobin measurement before initiating treatment in patients with severe G6PD deficiency or multiple comorbidities 2

Common Pitfalls and Caveats

• Avoid confusing G6PD contraindications with those of other antimicrobials like dapsone, which is explicitly contraindicated in G6PD deficiency 4
• Remember that screening for G6PD deficiency is recommended before starting therapy with known oxidant drugs in patients with predisposing racial or ethnic backgrounds (Mediterranean, African, Indian, or Southeast Asian descent) 1, 2